As of the latest Form 4 filed Jun 17, 2026.
What LivaNova PLC insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 37 most recent filings for LIVN.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-17 | 2026-06-15 | WILVER PETER M Director | FTax | −486.00 | $79.70 | $38.7K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | WILVER PETER M, Director | MExercise | +4.04K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | SCHERMERHORN TODD C Director | FTax | −486.00 | $79.70 | $38.7K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | SCHERMERHORN TODD C, Director | MExercise | +4.04K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Bianchi Francesco Director | SSale | −1.20K | $80.19 | $96.2K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Bianchi Francesco, Director | FTax | −486.00 | $79.70 | $38.7K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Bianchi Francesco, Director | MExercise | +4.04K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | PODLOGAR SUSAN M Director | FTax | −486.00 | $79.70 | $38.7K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | PODLOGAR SUSAN M, Director | MExercise | +4.04K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Barry James Christopher Director | FTax | −486.00 | $79.70 | $38.7K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Barry James Christopher, Director | MExercise | +4.04K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Tezel Ahmet Chief Innovation Officer | FTax | −1.03K | $79.70 | $82.3K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Tezel Ahmet, Chief Innovation Officer | MExercise | +2.96K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | KOZY WILLIAM A Director | FTax | −682.00 | $79.70 | $54.4K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | KOZY WILLIAM A, Director | MExercise | +5.68K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Enxing Seng Stacy Director | FTax | −486.00 | $79.70 | $38.7K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Enxing Seng Stacy, Director | MExercise | +4.04K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Story Brooke Director | FTax | −486.00 | $79.70 | $38.7K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Story Brooke, Director | MExercise | +4.04K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Zurbay Donald Director | FTax | −308.00 | $79.70 | $24.5K | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Zurbay Donald, Director | MExercise | +2.56K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-26 | Bianchi Francesco Director | SSale | −1.80K | $75.75 | $136K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Tezel Ahmet Chief Innovation Officer | FTax | −1.19K | $61.27 | $72.7K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Tezel Ahmet, Chief Innovation Officer | MExercise | +3.41K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Poletti Franco President, Cardiopulmonary | FTax | −1.37K | $61.27 | $83.9K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Poletti Franco, President, Cardiopulmonary | MExercise | +3.18K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Shvartsburg Alex Chief Financial Officer | FTax | −12.9K | $61.27 | $788K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Shvartsburg Alex, Chief Financial Officer | MExercise | +30.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Makatsaria Vladimir Chief Executive Officer | FTax | −11.2K | $61.27 | $684K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Makatsaria Vladimir, Chief Executive Officer | MExercise | +21.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Bolton Stephanie President, Global Epilepsy | FTax | −8.38K | $61.27 | $513K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Bolton Stephanie, President, Global Epilepsy | MExercise | +17.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Kozmina Natalia Chief Human Resources Officer | FTax | −1.37K | $61.27 | $84.2K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Kozmina Natalia, Chief Human Resources Officer | MExercise | +6.39K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-13 | 2026-03-11 | Poletti Franco President, Cardiopulmonary | FTax | −69.00 | $62.26 | $4.30K | No | Form 4 ↗ |
| 2026-03-13 | 2026-03-11 | Poletti Franco, President, Cardiopulmonary | FTax | −1.98K | $62.26 | $123K | No | Form 4 ↗ |
| 2026-03-13 | 2026-03-11 | Poletti Franco, President, Cardiopulmonary | MExercise | +2.14K | $57.60 | $123K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also LIVN’s full analysis or the market-wide insider trading feed. The tabs above jump to LIVN’s other SEC data.
Source: SEC Form 4 filings for LIVN, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.